The cloning of opioid receptors has provided direct structural evidence of the concept of "multiple opioid receptors" as powerful tool for physiological and pharmacological evaluation of their roles in both normal and acute pain states. 1-2 Delta-opioid receptors (DOP) are appealing drug targets for pain relief, due to the lack of unwanted side effects and the strong antinociceptive activity showed by their selective agonists thus a "smart" dual-acting opioid drug should be designed to be a full agonist of DOP and only a partial agonist toward the m-opioid receptors (MOR). Enkephalins are linear endogenous penta-peptides with high affinity for DOP regulating human nociception; numerous structural modifications have been explored during the last years to investigate the structure activity relationships (SAR) and to improve their selectivity; 3 H-Tyr-c[D-Pen-Gly-Phe-D-Pen]-OH (DPDPE) is the first synthetic prototype of highly selective constrained cyclic peptide for this receptor (Figure 1 ).
INTRODUCTION
The cloning of opioid receptors has provided direct structural evidence of the concept of "multiple opioid receptors" as powerful tool for physiological and pharmacological evaluation of their roles in both normal and acute pain states. [1] [2] Delta-opioid receptors (DOP) are appealing drug targets for pain relief, due to the lack of unwanted side effects and the strong antinociceptive activity showed by their selective agonists thus a "smart" dual-acting opioid drug should be designed to be a full agonist of DOP and only a partial agonist toward the m-opioid receptors (MOR). Enkephalins are linear endogenous penta-peptides with high affinity for DOP regulating human nociception; numerous structural modifications have been explored during the last years to investigate the structure activity relationships (SAR) and to improve their selectivity; 3 H-Tyr-c[D-Pen-Gly-Phe-D-Pen]-OH (DPDPE) is the first synthetic prototype of highly selective constrained cyclic peptide for this receptor (Figure 1 ).
AIM AND SCOPE
In this work we propose the design, synthesis and biological evaluation of new cyclic DPDPE analogues 7a-c containing o-, m-, p-xylene regioisomers respectively, as m/d mixed opioid receptor agonists, using in vitro and in vivo models to examine the antinociceptive activity. The C-terminal free carboxyl group in DPDPE improves the d/m selectivity, 4 then it has been maintained in our cyclic peptides. The cyclic peptides 7a-c have been also investigated by molecular docking study, to discern the structural influences of xylene regioisomers on the molecular interactions at the DOP.
SYNTHESIS AND CHARACTERIZATION
A side-chain-to-side-chain cyclization involving the two thiols groups and three dibromo-xylene regioisomers has been performed. The xylene-type bridging reaction utilizes the exquisite reactivity of dibromo-xylene scaffolds toward free thiols groups of D-Pen residues on compound 4, providing cyclic peptides containing two robust thioether bonds (5a-c). Compounds 7a-c have been characterized as TFA salts by UPLC-MS and 1 H-NMR. HCl, 1.1 equiv HOBt anhydrous, 3.3 equiv DIPEA, DMF under N 2 atmosphere, r.t., overnight; (e) 2.1 equiv of o-dibromo-xylene, 6 days for 5a, 1.3 equiv of m-dibromo-xylene, 4 days for 5b, 2.1 equiv of p-dibromo-xylene, 6 days for 5c, 2.6 equiv DIPEA in DMF under N 2 atmosphere, r.t.; (f) 1.1 equiv BocTyr-OH, 1.1 equiv EDC . HCl, 1.1 equiv HOBt anhydrous, 3.3 equiv DIPEA, DMF under N 2 atmosphere, r.t., overnight; (g) 4 equiv NaOH 1M in THF, 5h for 7a, 2 equiv NaOH 1M in THF, 2h for 7b, 3.5 equiv NaOH 1M in THF, 3h for 7c, r.t.
MOLECULAR DOCKING STUDY
To explore the impact of xylene bridge incorporation on the biological activity profile, compounds 7a-c and DPDPE were docked to the d-opioid receptor (PDB:4RWD) using Glide embedded in Maestro 9.2 and employing the generated grid around 10Å from the crystallographic ligand H-Dmt-Tic-Phe-Phe-NH 2 (DIPP-NH 2 ). 5 The best docking pose for each ligand was selected basing on XP scoring function.
The interaction between residue Asp128 and the amino terminus of each ligand is the most important and was preserved in all 5 models. The interaction with Arg192 has been also maintained in 7a and 7c, but 7b gained the best docking score and its best docking pose is stabilized by hydrogen bonds with Asp128, Lys214 and a saline bridge with Lys108. The xylene bridge enclosed in 7a-c is topically very similar to the Tic moiety in DIPP-NH 2 . 5 
IN VITRO BINDING ASSAYS
All the cyclic compounds 7a-c showed good binding profile for DOR, although they displayed a lower affinity than DPDPE (Figure 3 ). However, they showed a considerable higher affinity for MOR compared to DPDPE, indicating that the structural modifications on the parent compound significantly reduced its d-opioid receptor selectivity (Table 1) . This behavior closely resembles that of small cycle enkephalin analogues containing a thiourea bridge. 6 In particular, cyclic peptide 7a had the best K i value for DOR and MOR (Table 1 ). 
IN VIVO ANTINOCICEPTIVE TESTS
Antinociception assays have been also carried out to investigate the in vivo potential activity of the newly designed compounds. From the tail flick (TF) and hot plate (HP) tests we observed that compound 7b exerted a potent analgesic effect over 60% MPE, ranging from 15 to 60 minutes, after i.c.v. administration; this result has been also confirmed by formalin test (Figure 4 ). In the HP and TF test, drugs were injected i.c.v. at 23 nmol/mouse. In the formalin test, drugs were administered s.c. at 150 nmol/mouse, 15 minutes before formalin. **** is for P<0.0001, *** is for p<0.001, ** is for p<0.01, * is for p<0.05 vs V. N=8-10. Figure 3 .
CONCLUSIONS
 Compound 7b incorporating m-xylene bridge represents an exquisite example of wellbalanced equilibrium between d-opioid receptor affinity, m/d selectivity and analgesic potency.  The novel compounds induced robust and long-lasting antinociceptive effects both after central and local peripheral administration.  Our data validate the hypothesis that the design of novel chemical entities specifically targeted at known receptors will provide vantages for pain-relief in many pathological situations.
